Table 1.
Characteristics | Influenza A | Influenza B | Influenza C | Influenza D |
---|---|---|---|---|
Virus structure | Enveloped Eight gene segments Hemagglutinin (HA) and neuraminidase (NA) glycoproteins |
Enveloped Seven gene segments HA–esterase fusion glycoprotein |
||
Epidemiology | Antigenic shift and drift | Only antigenic drift | Only antigenic drift | Only antigenic drift |
Known hosts | Domestic and wild animals and avian species | Humans, pigs, and seals | Humans and pigs | Humans and livestock (cattle, pigs, and goats) |
Clinical manifestation | Pandemic potential could cause high mortality | Can cause severe disease in elderly and high-risk populations | Mild seasonal disease predominantly in children | Mild disease in humans across ages |
Available diagnostics | Rapid diagnostic tests (i.e., antigen detection); rapid molecular assays (nucleic acid detection); immunofluorescence; and cell culture | Real-time PCR and cell culture | ||
Treatments | NA inhibitors: zanamivir, oseltamivir, and peramivir. Laninamivir investigational in USA. | NA inhibitors: zanamivir, oseltamivir, and peramivir. Laninamivir investigational in USA. | Supportive symptom management | Supportive symptom management |
Adamantanes: amantadine and rimantadine (notrecommended in USA due to resistance) |